Related Experiment Video
Updated: Aug 19, 2026

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
Published on: November 28, 2025
Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort
Christopher B R Funk1, Asuri N Prasad, Patrick Frosk
1Department of Pathology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Insights
Glutaric acidemia type 1 (GA-1), a GCDH deficiency disorder, causes striatal damage and movement issues. Neuron loss occurs early after crises and doesn't worsen, with elevated organic acids found throughout the brain.
Area of Science:
- Neuroscience
- Metabolic Disorders
- Genetics
Background:
- Glutaric acidemia type 1 (GA-1) is an inherited metabolic disorder caused by glutaryl-CoA dehydrogenase (GCDH) deficiency.
- It typically manifests in infancy with acute encephalopathy, leading to striatal damage and dystonic movement disorders.
Observation:
- This study examined neuropathological features in six North American aboriginal individuals with GA-1.
- Key observations included macrocephaly in some, striatal atrophy with significant loss of medium-sized neurons in all cases.
Findings:
- Neuron loss in the striatum occurs acutely after encephalopathic crises and does not progress over time.
- Novel findings include mild loss of large striatal neurons, white matter spongiosis in the brainstem, and early lymphocytic infiltrates.
- Elevated concentrations of glutaric acid (GA) and 3-hydroxy-glutaric acid (3-OH-GA) were detected in all brain regions, without regional or age-specific differences.
Implications:
- Understanding the timing and progression of neuropathology in GA-1 is crucial for developing targeted treatments.
- The study highlights the need for a suitable animal model to further investigate GA-1 pathogenesis and test therapeutic strategies.
- The role of organic acids as potential neurotoxins or osmolytes in GA-1 warrants further investigation.
Abstract:
Glutaric acidemia type 1 (GA-1) is an autosomal recessive disorder characterized by a deficiency of glutaryl-CoA dehydrogenase (GCDH) activity. GA-1 is often associated with an acute encephalopathy between 6 and 18 months of age that causes striatal damage resulting in a severe dystonic movement disorder. Ten autopsy cases have been previously described. Our goal is to understand the disorder better so that treatments can be designed. Therefore, we present the neuropathological features of six additional cases (8 months-40 years), all North American aboriginals with the identical homozygous mutation. This cohort displays similar pathological characteristics to those previously described. Four had macroencephaly. All had striatal atrophy with severe loss of medium-sized neurons. We present several novel findings. This natural time course study allows us to conclude that neuron loss occurs shortly after the encephalopathical crisis and does not progress. In addition, we demonstrate mild loss of large striatal neurons, spongiform changes restricted to brainstem white matter and a mild lymphocytic infiltrate in the early stages. Reverse transcriptase-PCR to detect the GCDH mRNA revealed normal and truncated transcripts similar to those in fibroblasts. All brain regions demonstrated markedly elevated concentrations of GA (3770-21 200 nmol/g protein) and 3-OH-GA (280-740 nmol/g protein), with no evidence of striatal specificity or age dependency. The role of organic acids as toxic agents and as osmolytes is discussed. The pathogenesis of selective neuronal loss cannot be explained on the basis of regional genetic and/or metabolic differences. A suitable animal model for GA-1 is needed.
Related Concept Videos
Lysosomal Hydrolases
Inborn Errors of Metabolism
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

